Joachim Eeckhout, Author at Labiotech.eu - Page 13 of 16

About

Founder & Managing Director at Labiotech.eu. While I was studying biotechnology in Paris, I got frustrated by the lack of digital media available for the industry and decided to fix it! I launched Labiotech.eu in 2014 and grew it to the largest community for biotech professionals in Europe! Other than biotech news, I’m also a heavy reader of Sci-Fi and Fantasy.

Articles by Joachim Eeckhout

Ynsectimage

News and Trends 27 Apr 2015

Ynsect: what’s behind this Yellow Biotech champion?

How do you manage a planet with a growing population with increasing consumption needs when you only have a limited amount of ressources available? Everybody knows it’s a never-ending debate, but some companies are grabbing their chance to change the world. Ynsect is one of the many firms trying to do so, and could be a future champion of the Yellow Biotech […]

April 27, 2015 - 5 minutesmins - By Joachim Eeckhout

novonordisk

News and Trends 24 Apr 2015

Novo Nordisk Takes on One of the World’s Biggest Markets: Obesity

Novo Nordisk, the Danish global healthcare company, received the all clear a few month ago from the US, EU and Canada to launch and sell a new treatment for Weight Management, Saxenda. The company announced the launch of Saxenda in the US, who present the treatment as an adjunct to a reduced-calorie diet and increased physical activity for chronic […]

April 24, 2015 - 2 minutesmins - By Joachim Eeckhout

IBI smartbone

News and Trends 22 Apr 2015

[Interview] Smartbone, using bioengineering to repair your bones!

Orthobiology is a field of biomedical technology, which develops new devices and products for skeletal regenerative medicine. IBI sa (Industrie Biomediche Insubri sa) is a Swiss-based company excelling in this field. I met Giuseppe Perale, co-founder and President of the company, who not only gave me the big picture on this field, but also on […]

April 22, 2015 - 5 minutesmins - By Joachim Eeckhout

bayer berkeley Hemophilia

News and Trends 16 Apr 2015

Bayer Healthcare invests €94 Million in its Hemophilia pipeline

Bayer HealthCare, a subgroup of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. Yesterday, the company announced a €94M investment in its Berkeley (California) manufacturing site to build a product testing facility that will support the next generation of treatments for patients with hemophilia A. David […]

April 16, 2015 - 2 minutesmins - By Joachim Eeckhout

road microalgae

News and Trends 15 Apr 2015

Will the roads of the future be paved with microalgae?

In contrast to first generation biofuels, where edible plants were suggested to be grown to obtain oil, microalgae raise as a very promising source alternative to fossil fuels. For the first time, they have been used to make bio-bitumen. Some French public institutes (Centre National de la Recherche Scientifique, Université de Nantes, Ecole des Mines de Nantes) in partnership […]

April 15, 2015 - 2 minutesmins - By Joachim Eeckhout

uniqure1

News and Trends 7 Apr 2015

A New Key Strategic Collaboration Between BMS and UniQure

Last month, Bristol-Myers Squibb (BMS) and UniQure, the Dutch pioneer in human gene therapy, were at the forefront of the scene after having agreed on two collaborations, respectively, an agreement between Bavarian Nordic & BMS and a collaboration between Sympromics & UniQure. A few days ago, they announced an exclusive strategic collaboration to develop gene therapies for cardiovascular […]

April 7, 2015 - 3 minutesmins - By Joachim Eeckhout

ADVERTISEMENT

intrexon

News and Trends 31 Mar 2015

Merck Serono and Intrexon, to develop CAR-T Therapy

Merck Sereno, the biopharmaceutical business of Merck, and the synthetic biology leader Intrexon announced yesterday an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. CAR-T cells are genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells. When CAR-T cells bind to a target, […]

March 31, 2015 - 2 minutesmins - By Joachim Eeckhout

cellectis

News and Trends 26 Mar 2015

With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever

Exactly one month ago, the article “Cellectis is preparing its IPO in the U.S” explained Cellectis prepared an IPO to be listed on the NASDAQ. Yesterday, the company announced the pricing of its initial public offering. Its goal is to raise €197M and up to €226.8M in case of allotment. A large amount of ressources […]

March 26, 2015 - 2 minutesmins - By Joachim Eeckhout

Syngenta

News and Trends 19 Mar 2015

Syngenta corn trait expansion further continues thanks the Vietnamese approval

A few days ago, Syngenta announced that the Vietnamese Ministry of Natural Resources and Environment has approved its Bt11 x GA21 double stack corn seed for commercial cultivation in the country. Syngenta, one of the world’s leading companies in the field of Green Biotechnology, have more than 28,000 employees in over 90 countries. The company […]

March 19, 2015 - 2 minutesmins - By Joachim Eeckhout

Valneva

News and Trends 18 Mar 2015

Valneva penetrates Chinese Market thanks to a license agreement

A few months ago, the article “An Anglo-French Partnership To Cure Hepatitis B” related Valneva partnerships with Immune Targeting Systems. Today Valneva, a leading pure play vaccines biotech company is again on the front of the stage by announcing the exclusive license agreement with the Chinese company Jianshun Biosciences to commercialize Valneva’s EB66 cell line […]

March 18, 2015 - 2 minutesmins - By Joachim Eeckhout

Philip Joachim Tee shirt Logogoodsize

Inside Labiotech 17 Mar 2015

Labiotech: Taking it to the next level

Today is an exciting day for us! In its short history, Labiotech has brought a fresh dynamic and original concepts to the Biotech media industry. So far, 5 Tours have been accomplished worldwide with 5 more to come still in 2015. For the first time, Labiotech has filmed entire biotech companies and ecosystems, to cover the latest […]

March 17, 2015 - 2 minutesmins - By Joachim Eeckhout

LaBiotech Zurich Life Science Day3

News and Trends 16 Mar 2015

Against Being Against GMOs: The Golden Rice Story

At the Zurich Life Science Day, I had the pleasure of hearing the keynote speaker, Professor Ingo Potrykus, Professor Emeritus of Plant Sciences at the Institute of Plant Sciences at ETH Zurich and creator of Golden Rice (GR). At 82 years old, he has the liveliness of someone much younger than him. While initially the […]

March 16, 2015 - 6 minutesmins - By Joachim Eeckhout

ADVERTISEMENT